Emergent BioSolutions
EBS
#6713
Rank
NZ$1.13 B
Marketcap
NZ$21.36
Share price
8.06%
Change (1 day)
38.95%
Change (1 year)

P/E ratio for Emergent BioSolutions (EBS)

P/E ratio as of December 2025 (TTM): 8.74

According to Emergent BioSolutions 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 8.74468. At the end of 2024 the company had a P/E ratio of -2.63.

P/E ratio history for Emergent BioSolutions from 2007 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-2.631533.19%
2023-0.1613-93.88%
2022-2.64-126.26%
202110.0-35.24%
202015.5-69.54%
201950.97.32%
201847.499%
201723.8-16.55%
201628.613.48%
201525.2-11.29%
201428.46.11%
201326.78.33%
201224.7

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Merck
MRK
13.2 50.98%๐Ÿ‡บ๐Ÿ‡ธ USA
SIGA Technologies
SIGA
15.0 72.08%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
13.7 56.59%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
-8.01-191.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
15.4 75.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
47.8 446.91%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Soligenix
SNGX
-0.4784-105.47%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.